

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7469743

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
CATHWORKS LTD.	07/11/2022

RECEIVING PARTY DATA

Name:	COVIDIEN GROUP S.Á R.L.
Street Address:	3B BOULEVARD
City:	PRINCE HENRI
State/Country:	LUXEMBOURG
Postal Code:	1724

PROPERTY NUMBERS Total: 36

Property Type	Number
Application Number:	14437205
Application Number:	15952701
Application Number:	16291916
Application Number:	16859239
Application Number:	14040688
Application Number:	15640138
Application Number:	15985359
Application Number:	16200230
Application Number:	16551506
Application Number:	14761086
Application Number:	14761079
Application Number:	15809704
Application Number:	16680226
Application Number:	14761064
Application Number:	16278644
Application Number:	16785196
Application Number:	15031815
Application Number:	16578839
Application Number:	15959024
Application Number:	16600871

PATENT

Property Type	Number
Application Number:	15910900
Application Number:	16538579
Application Number:	16489289
Application Number:	17700899
Application Number:	16826594
Application Number:	17391900
Application Number:	17493518
Application Number:	17712979
Application Number:	17751294
Application Number:	17516319
Application Number:	17391943
Application Number:	17599962
Application Number:	17762681
Application Number:	63247040
Application Number:	17627594
Application Number:	63308550

CORRESPONDENCE DATA

Fax Number: (949)760-9502

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 9497600404

Email: efilings@knobbe.com

Correspondent Name: KNOBBE, MARTENS, OLSON & BEAR LLP

Address Line 1: 2040 MAIN STREET

Address Line 2: 14TH FLOOR

Address Line 4: IRVINE, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER:	CATHW.000GEN
NAME OF SUBMITTER:	SABING LEE
SIGNATURE:	/Sabing Lee/
DATE SIGNED:	08/04/2022

Total Attachments: 15

source=2022-07-11 IP Security Agreement (002)#page1.tif
source=2022-07-11 IP Security Agreement (002)#page2.tif
source=2022-07-11 IP Security Agreement (002)#page3.tif
source=2022-07-11 IP Security Agreement (002)#page4.tif
source=2022-07-11 IP Security Agreement (002)#page5.tif
source=2022-07-11 IP Security Agreement (002)#page6.tif
source=2022-07-11 IP Security Agreement (002)#page7.tif
source=2022-07-11 IP Security Agreement (002)#page8.tif
source=2022-07-11 IP Security Agreement (002)#page9.tif

source=2022-07-11 IP Security Agreement (002)#page10.tif
source=2022-07-11 IP Security Agreement (002)#page11.tif
source=2022-07-11 IP Security Agreement (002)#page12.tif
source=2022-07-11 IP Security Agreement (002)#page13.tif
source=2022-07-11 IP Security Agreement (002)#page14.tif
source=2022-07-11 IP Security Agreement (002)#page15.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified, this "Agreement") is entered into as of July 11, 2022, by and between CATHWORKS LTD., an Israeli privately held company, having its principal executive offices at 3 Rapaport St., Kfar Saba, Israel ("Grantor") and Covidien Group S.à r.l., a Luxembourg company, whose registered office is at 3b Boulevard Prince Henri, Luxembourg 1724 ("Lender").

RECITALS

A. Lender and Grantor are entering into a Floating Charge Agreement as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"). Capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement.

B. The Secured Obligations are secured by the Collateral, including without limitation, all of Grantor's Intellectual Property, which include, *inter alia*, Intellectual Property rights which are registered or filed with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, as detailed in Exhibits A, B and C attached hereto, respectively (collectively, "Intellectual Property").

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, Grantor and Lender hereby agree:

AGREEMENT

To secure the Secured Obligations, Grantor grants Lender a security interest in all of Grantor's right, title and interest in its Intellectual Property (other than any Excluded Assets). Grantor hereby confirms that the attached schedules of Grantor's copyright, patent and trademark applications and registrations (owned solely or jointly by Grantor), attached hereto as Exhibits A, B and C hereto, respectively, are complete and accurate as of the date hereof.

Notwithstanding anything to the contrary herein, it is hereby clarified that with respect to such portion of the Intellectual Property which is or was developed with funding provided by the Israeli Innovation Authority (such Intellectual Property, the "Funded IP"), the security herein shall be subject to the consent of the Israeli Innovation Authority, in the form attached hereto as Exhibit D (the "IIA Consent"), and that the sale, assignment or another transfer of the Funded IP may be subject to the IIA Consent and the provisions of applicable grant certificates or undertaking issued by the IIA and applicable Israeli laws and regulations and any payment obligation imposed thereunder.

Grantor hereby authorizes Lender to (a) modify this Agreement unilaterally solely by amending the exhibits to this Agreement to include any Intellectual Property which Grantor registers, files, or otherwise obtains in the United States of America or in any other jurisdiction (as sole or joint owner) subsequent to the date of this Agreement, and (b) file a duplicate of this Agreement containing amended exhibits reflecting such new Intellectual Property with the United States Patent and Trademark Office or in any other jurisdiction, as reasonably practicable.

This Agreement shall be governed by, and construed in accordance with, the laws of the State of Israel, without regard to the conflict of laws provisions thereof. Any dispute arising under or with respect to this Agreement shall be resolved exclusively in the appropriate court in Tel-Aviv, Israel. Each of the parties hereby irrevocably consents to the exclusive jurisdiction of such courts and waives and agrees not to assert any objection to the jurisdiction or convenience thereof. This Agreement may be executed in

counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

The rights, powers and remedies of Lender under this Agreement shall be in addition to all rights, powers and remedies given to Lender by virtue of any applicable law, rule or regulation of any governmental authority, any Loan Document or any other agreement, all of which rights, powers, and remedies shall be cumulative and may be exercised successively or concurrently without impairing Lender's rights hereunder. Grantor waives any right to require Lender to proceed against any person or entity or to exhaust any Collateral or to pursue any remedy in Lender's power.

Except as otherwise expressly limited herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors and assigns of the parties hereto. Except as otherwise expressly stated to the contrary herein, each of the parties hereto shall not assign or transfer any of its rights or obligations hereunder absent the prior written consent of the other party, which consent shall not be unreasonably withheld. Anything herein to the contrary notwithstanding but subject to the following sentence, the Lender may assign or transfer its rights and obligations under this Agreement to any of its affiliates without having to obtain the Grantor's consent.

Any notice or other communication required or permitted to be delivered to any party under this Agreement shall be made in accordance with Section 14 ('Notices') of the Note.

If to Grantor, to: Cathworks Ltd.
3 Rapaport St., Kfar Saba, Israel
Attention: Ramin Mousavi, President & CEO
Email: ramin.mousavi@cath.works

With a copy to (which shall not constitute notice):

Matry, Meiri, Wacht & Co.
4 Ariel Sharon St.
Givatayim, Israel
Attn: Keren Wacht
Email: keren@mamlaw.co.il
Telephone: 972-3-610-9055
Facsimile: 972-3-610-9009

If to Lender, to: c/o Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, MN 55432-5604

with separate copies thereof addressed to:

Attention: Chris Cleary, VP Corporate Development
Facsimile: (763) 367-1624
Email: chris.cleary@medtronic.com

With a copy to (which shall not constitute notice):

Meitar Law Offices
16 Abba Hillel Road
Ramat Gan 5250608, Israel
Attention: Mike Rimon; Ran Camchy
Email: mrimon@meitar.com; ranca@meitar.com
Telephone: +972-3-610-3100
Facsimile: +972-3-610-3687

No failure on the part of Lender to exercise and no delay in exercising any power or right under this Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any power or right preclude any other or further exercise thereof or the exercise of any other power or right. The remedies herein and in any other instrument, document or agreement delivered or to be delivered to the Lender hereunder or in connection herewith are cumulative and not exclusive of any remedies provided by law. No notice to or demand on the Grantor not required under the Loan Documents shall entitle the Lender to any other or further notice or demand in similar or other circumstances or constitute a waiver of the right of the Lender or the holder of the Note to any other or further action in any circumstances without notice or demand. No amendment, modification or waiver of any provision of this Agreement or consent to any departure by the Grantor therefrom shall be effective unless the same shall be in writing and signed by the Lender and the Grantor, and then such amendment, modifications, waiver or consent shall be effective only in the specific instances and for the specific purpose for which given.

This Agreement and the other Loan Documents constitute the full and entire understanding and agreement among the parties with regard to the subject matters hereof and thereof. The preamble, exhibits and schedules hereto are part of this Agreement.

References in this Agreement and each of the other Loan Documents to any document, instrument or agreement (a) includes all exhibits, schedules and other attachments thereto, (b) includes all documents, instruments or agreements issued or executed in replacement thereof, and (c) means such document, instrument or agreement, or replacement or predecessor thereto, as amended, modified and supplemented from time to time and in effect at any given time. The words "hereof," "herein" and "hereunder" and words of similar import when used in this Agreement or any other Loan Document refer to this Agreement or such other Loan Document, as the case may be, as a whole and not to any particular provision of this Agreement or such other Loan Document, as the case may be. The words "include" and "including" and words of similar import when used in this Agreement or any other Loan Document shall not be construed to be limiting or exclusive.

Section headings herein are included for convenience of reference only and shall not constitute a part hereof for any other purpose or be given any substantive effect.

In case any provision in or obligation hereunder shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

All representations and warranties made herein shall survive the execution and delivery hereof.

Without derogating from the provisions contained herein, Lender shall pay for the expenses incurred in connection with the preparation, filing, perfection and removal of the security interest to this Agreement.


This Agreement and the security interest granted hereunder to the Lender shall terminate and be removed upon the final payment and full of all Secured Obligations. Upon termination of this Agreement and the security interest granted to the Lender hereunder, the Lender shall execute all documents reasonably necessary to remove the security interest granted by the Grantor hereunder and take any action reasonably necessary to remove the security interest granted by the Grantor hereunder, including without limitation, the filing of termination statements with the United States Patent and Trademark Office, the United States Copyright Office or with any similar office in another jurisdiction, as applicable, for the applicable Intellectual Property. In the event of contradiction between this Agreement and the Security Agreement, the provisions of this Agreement shall prevail and govern.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

CATHWORKS LTD

By:  _____

Title: *President & CEO*


Name: *Ramin Mousavi*

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

LENDER:

COVIDIEN GROUP SARL

By:  _____
Name: Erik De Gres
Title: General Manager

[Signature page to Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

<u>Description</u>	<u>Registration Number</u>	<u>Registration Date</u>
--------------------	--------------------------------	--------------------------

N/A

EXHIBIT B

Patents

Issued U.S. Patents

Title	Patent No.	Application No.	Filing Date	Issue Date
AUTOMATED MEASUREMENT SYSTEM AND METHOD FOR CORONARY ARTERY DISEASE SCORING	9,943,233	14/437,205	21-Apr-2015	17-Apr-2018
AUTOMATED MEASUREMENT SYSTEM AND METHOD FOR CORONARY ARTERY DISEASE SCORING	10,219,704	15/952,701	13-Apr-2018	05-Mar-2019
AUTOMATED MEASUREMENT SYSTEM AND METHOD FOR CORONARY ARTERY DISEASE SCORING	10,631,737	16/291,916	04-Mar-2019	28-Apr-2020
AUTOMATED MEASUREMENT SYSTEM AND METHOD FOR CORONARY ARTERY DISEASE SCORING	11,278,208	16/859,239	27-Apr-2020	22-Mar-2022
VASCULAR FLOW ASSESSMENT	9,858,387	14/040,688	29-Sep-2013	02-Jan-2018
VASCULAR FLOW ASSESSMENT	9,977,869	15/640,138	30-Jun-2017	22-May-2018
VASCULAR FLOW ASSESSMENT	10,141,074	15/985,359	21-May-2018	27-Nov-2018
VASCULAR FLOW ASSESSMENT	10,395,774	16/200,230	26-Nov-2018	27-Aug-2019
VASCULAR FLOW ASSESSMENT	10,803,994	16/551,506	26-Aug-2019	13-Oct-2020
CALCULATING A FRACTIONAL FLOW RESERVE	10,595,807	14/761,086	15-Jul-2015	24-Mar-2020
CREATING A VASCULAR TREE MODEL	9,814,433	14/761,079	15-Jul-2015	14-Nov-2017
CREATING A VASCULAR TREE MODEL	10,470,730	15/809,704	10-Nov-2017	12-Nov-2019
CREATING A VASCULAR TREE MODEL	11,295,864	16/680,226	11-Nov-2019	05-Apr-2022
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	10,210,956	14/761,064	15-Jul-2015	19-Feb-2019
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	10,559,388	16/278,644	18-Feb-2019	11-Feb-2020
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	11,081,237	16/785,196	07-Feb-2020	03-Aug-2021
VASCULAR CHARACTERISTIC DETERMINATION WITH CORRESPONDENCE MODELING OF A VASCULAR TREE	10,424,063	15/031,815	25-Apr-2016	24-Sep-2019
VASCULAR CHARACTERISTIC DETERMINATION WITH CORRESPONDENCE MODELING OF A VASCULAR TREE	11,138,733	16/578,839	23-Sep-2019	05-Oct-2021
VASCULAR SELECTION FROM IMAGES	10,441,235	15/959,024	20-Apr-2018	15-Oct-2019
VASCULAR PATH EDITING USING ENERGY FUNCTION MINIMIZATION	11,160,524	16/600,871	14-Oct-2019	02-Nov-2021
SYSTEM FOR VASCULAR ASSESSMENT	10,376,165	15/910,900	02-Mar-2018	13-Aug-2019
SYSTEM FOR VASCULAR ASSESSMENT	11,076,770	16/538,579	12-Aug-2019	03-Aug-2021
SHELL-CONSTRAINED LOCALIZATION OF VASCULATURE	11,017,531	16/489,289	27-Aug-2019	25-May-2021

Pending U.S. Patent Applications

Title	Application No.	Filing Date
AUTOMATED MEASUREMENT SYSTEM AND METHOD FOR CORONARY ARTERY DISEASE SCORING	17/700,899	22-Mar-2022
CALCULATING A FRACTIONAL FLOW RESERVE	16/826,594	23-Mar-2020
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	17/391,900	02-Aug-2021

VASCULAR CHARACTERISTIC DETERMINATION WITH CORRESPONDENCE MODELING OF A VASCULAR TREE	17/493,518	04-Oct-2021
CREATING A VASCULAR TREE MODEL	17/712,979	04-Apr-2022
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	17/751,294	23-May-2022
VASCULAR SELECTION FROM IMAGES	17/516,319	01-Nov-2021
SYSTEM FOR VASCULAR ASSESSMENT	17/391,943	02-Aug-2021
METHODS AND APPARATUS FOR ANGIOGRAPHIC IMAGE SELECTION	17/599,962	29-Sep-2021
METHODS, APPARATUS, AND SYSTEM FOR SYNCHRONIZATION BETWEEN A THREE-DIMENSIONAL VASCULAR MODEL AND AN IMAGING DEVICE	17/762,681	22-Mar-2022
FOUR-DIMENSIONAL MOTION ANALYSIS OF PATIENT'S CORONARY ARTERIES AND MYOCARDIAL WALL	63/247,040	22-Sep-2021
FUNCTIONAL IMPACT OF VASCULAR LESIONS	17/627,594	14-Jan-2022
VASCULAR TREE SEGMENTATION	63/308,550	10-Feb-2022

Issued Foreign Patents

Title	Patent No.	Application No.	Country	Filing Date	Issue Date
AUTOMATED MEASUREMENT SYSTEM AND METHOD FOR CORONARY ARTERY DISEASE SCORING	EP2943902	13796169.4	Europe (validated in Germany, United Kingdom, Netherlands)	24-Oct-2013	11-Mar-2020
CALCULATING A FRACTIONAL FLOW RESERVE	EP2946319	14708097.2	Europe (validated in Germany, United Kingdom, Netherlands)	15-Jan-2014	12-Aug-2020
CALCULATING A FRACTIONAL FLOW RESERVE	239960	239960	Israel	14-Jan-2014	01-Oct-2021
CALCULATING A FRACTIONAL FLOW RESERVE	6636331	2015-552198	Japan	15-Jan-2014	29-Jan-2020
CALCULATING A FRACTIONAL FLOW RESERVE	7039442	2018-216396	Japan	19-Nov-2018	11-Mar-2022
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	2946321	14710059.8	Europe (validated in Germany, United Kingdom, Netherlands)	15-Jan-2014	02-Sep-2020
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	239961	239961	Israel	14-Jan-2014	01-Nov-2019
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	6542129	2015-553226	Japan	15-Jan-2014	10-Jul-2019
DIAGNOSTICALLY USEFUL RESULTS IN REAL TIME	6790179	2019-109686	Japan	12-Jun-2019	25-Nov-2020
VASCULAR CHARACTERISTIC DETERMINATION WITH CORRESPONDENCE	245180	245180	Israel	22-Oct-2014	01-Apr-2021

MODELING OF A VASCULAR TREE					
SYSTEM FOR VASCULAR ASSESSMENT	7036742	2018-561021	Japan	16-May-2017	07-Mar-2022

Pending Foreign Patent Applications


Title	Application No.	Country	Filing Date
AUTOMATED MEASUREMENT SYSTEM AND METHOD FOR CORONARY ARTERY DISEASE SCORING	20162040.8	Europe	10-Mar-2020
CALCULATING A FRACTIONAL FLOW RESERVE	20190353.1	Europe	10-Aug-2020
CALCULATING A FRACTIONAL FLOW RESERVE	2020-189338	Japan	13-Nov-2020
VASCULAR CHARACTERISTIC DETERMINATION WITH CORRESPONDENCE MODELING OF A VASCULAR TREE	21186306.8	Europe	19-Jul-2021
VASCULAR SELECTION FROM IMAGES	17798882.1	Europe	16-May-2017
VASCULAR SELECTION FROM IMAGES	2018-561035	Japan	16-May-2017
VASCULAR SELECTION FROM IMAGES	263066	Israel	16-May-2017
SYSTEM FOR VASCULAR ASSESSMENT	17798881.3	Europe	16-May-2017
SYSTEM FOR VASCULAR ASSESSMENT	2022-032262	Japan	02-Mar-2022
SYSTEM FOR VASCULAR ASSESSMENT	263065	Israel	16-May-2017
METHODS AND APPARATUS FOR ANGIOGRAPHIC IMAGE SELECTION	20784469.7	Europe	26-Mar-2020
METHODS AND APPARATUS FOR ANGIOGRAPHIC IMAGE SELECTION	2021-558763	Japan	26-Mar-2020
METHODS AND APPARATUS FOR ANGIOGRAPHIC IMAGE SELECTION	286814	Israel	26-Mar-2020
METHODS, APPARATUS, AND SYSTEM FOR SYNCHRONIZATION BETWEEN A THREE-DIMENSIONAL VASCULAR MODEL AND AN IMAGING DEVICE	2020781104.3	Europe	23-Sep-2020
FUNCTIONAL IMPACT OF VASCULAR LESIONS	20843503.2	Europe	17-Jul-2020
FUNCTIONAL IMPACT OF VASCULAR LESIONS	2022-503575	Japan	17-Jul-2020
FUNCTIONAL IMPACT OF VASCULAR LESIONS	289945	Israel	17-Jul-2020

EXHIBIT C

Trademarks

"FFRANGIO" (Word Mark)			
Country	Filing Date Application No.	Registration Date Registration No.	Status
Israel	26-Jan-2016 282159	03-Sep-2017 282159	Registered
European Union	18-Jul-2016 015672868	22-Nov-2016 015672868	Registered
Great Britain (clone)	18-Jul-2016 UK00915672868	22-Nov-2016 UK00915672868	Registered
Japan	20-Jul-2016 2016-077742	27-Jan-2017 5917227	Registered
Republic of Korea	22-Jul-2016 45-2016-0006054	05-Apr-2017 45-0072854	Registered
China	22-Jul-2016 20732332	14-Sep-2017 20732332	Registered
USA	18-Jul-2016 87/106.889	05-Oct-2021 6,513,225	Registered

"CATHWORKS" (Word Mark)			
Country	Filing Date Application No.	Registration Date Registration No.	Status
Republic of Korea (MADRID)	20-Jul-2016 1317439	20-Jul-2016 1317439	Registered
Japan (MADRID)	20-Jul-2016 1317439	20-Jul-2016 1317439	Registered
China (MADRID)	20-Jul-2016 1317439	20-Jul-2016 1317439	Registered
Israel	26-Jan-2016 282158	03-Sep-2017 282158	Registered
WIPO (MADRID)	20-Jul-2016 1317439	20-Jul-2016 1317439	Registered
USA (MADRID)	20-Jul-2016 79/195.466	07-Mar-2017 5,153,390	Registered
European Union (MADRID)	20-Jul-2016 1317439	20-Jul-2016 1317439	Registered
Great Britain (Clone)	20-Jul-2016 UK00801317439	20-Jul-2016 UK00801317439	Registered

 "FFR ANGIO" (Design Mark)			
Country	Filing Date Application No.	Registration Date Registration No.	Status
USA	01-Dec-2017	05-Oct-2021	Registered
	87/704,628	6,511,709	
USA	01-Dec-2017	24-Sep-2019	Registered
	87/981,504	5,869,388	


 "FFR CT" (Design Mark)			
Country	Filing Date Application No.	Registration Date Registration No.	Status
USA	19-Jan-2022	—	Pending
	97/226,976		

EXHIBIT D

IIA Consent

תאריך הפקה: כ"ח בסיון תשפ"ב

27/06/2022

לכבוד:

מנכ"ל החברה: קתורקס בע"מ

ח.פ. 514882836

מספר החברה ברשות 9987

כתובת: רפפורט 03

כפר סבא, 4465141

התשובה נשלחה באמצעות דוא"ל לכתובת: mica@cath.works

א.ג.ג.

הנדון: הלוואה ושעבוד

ועדת המחקר שהתקיימה בתאריך 22/06/2022

הריני להודיעכם החלטת ועדת המחקר:

רשמנו את הודעתכם בשם חברת קתורקס בע"מ (ח"פ מספר 6-488283-51) (להלן: "החברה"), כדלהלן:

Covidien Group S.à r.l. הינה בעלת מניות בחברה המאוגדת מחוץ למדינת ישראל ("בעלת המניות"). החברה נמצאת בהליכים מתקדמים של משא ומתן עם בעלת המניות בקשר עם עסקה במסגרתה, בין היתר, תעניק בעלת המניות מימון בדרך של הלוואה, שיועבר לחברה בתשלומים ועשוי להגיע לסך של 75,500,000 דולר ארה"ב (או סכום גבוה יותר, בהתאם להסכמות בין הצדדים) ("המימון"). אחד מהתנאים שהציבה בעלת המניות לחתימה על מסמכי העסקה ולהעברת המימון, הוא כי החברה תשעבד, כבטוחה להבטחת התחייבויותיה של החברה בקשר עם המימון, את כל נכסיה, ובכלל כך גם זכויות קניין רוחני מסוימות של החברה אשר פותחו במסגרת פרויקטים אשר מומנו בחלקם על ידי הרשות במסגרת התיקים ("הקניין הרוחני").

* האישור הינו בכפוף לחתימת המלווה על כתב התחייבות

** שעבוד הידע ומימושו ייעשה בהתאם לדיני מדינת ישראל ויירשם אצל רשם החברות בישראל. במקרה שהשעבוד ביחס לידע ימומש, תהיה מכירת הידע והעברתו במסגרת תהליכי המימוש, לרבות במקרה שרוכשת הידע תהיה המלווה עצמה, כפופה לאישור ועדת המחקר. כמו כן, העברת הידע במסגרת תהליך המימוש תהיה מותנית בהסכמת מקבל הידע לקבל על עצמו את החובות לפי חוק החדשנות, ולפי תנאי הוראות המועצה ומסלול ההטבה, ובכלל זה החובה שלא להעביר את הידע לאחר, אלא בהסכמת ועדת המחקר, והחובה לשלם תמלוגים.



רשות החדשנות
Israel Innovation
Authority

בכבוד רב,
ד"ר דרור בן

מנכ"ל הרשות